# POLARGO (NCT04182204)

> A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04182204
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: Polatuzumab Vedotin; Rituximab; Gemcitabine; Oxaliplatin
- Enrollment: 270
- Primary outcome: Stage 1: Number of Participants With Adverse Events (AEs)
- Primary outcome: Stage 1: Number of Participants With Peripheral Neuropathy (PN)
- Primary outcome: Stage 2: Overall Survival (OS)

## Commentary we found

- YouTube: 19
- Podcasts: 19
- X threads: 18
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=polargo-nct04182204

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04182204", "email": "<work email>"}; the inbox owner confirms by the emailed link.